Health ❯ Respiratory Diseases

Chronic Obstructive Pulmonary Disease

Asthma Diagnosis Poor Air Quality Exacerbations Complications Symptoms Medications Non-Cystic Fibrosis Bronchiectasis Drug Therapies Treatment Options Mortality Risk Causes Awareness Campaigns Epidemiology Risk Factors COPD Statistics Tobacco Use Bronchial Asthma

AstraZeneca’s COPD Antibody Tozorakimab Succeeds in Two Phase 3 Trials

The IL-33 drug cut COPD flare-ups, hinting at a new class.

Emphysema Seen on Lung Screening CT Predicts Higher Long-Term Mortality, 25-Year Study Finds

GSK Closes $12 Billion Licensing Pact for Hengrui’s COPD Therapy and 11 Preclinical Assets

EU Regulator Recommends AstraZeneca’s Low-Carbon COPD Inhaler

Merck to Acquire Verona Pharma in $10 Billion Deal for Ohtuvayre COPD Therapy